EUCTR2013-002737-38-DE进行中（未招募）1 期
A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - EUCROSS
niversity of Cologne0 个研究点目标入组 30 人开始时间: 2014年2月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients with adenocarcinoma of the lung that is locally advanced or metastatic independent from the number of prior lines of therapy, i.e. including non-pretreated patients (UICC stage IIIB or IV)
- •Positive result of ROS1 translocation by central FISH-testing is mandatory.
- •Ability to swallow pills
- •Age > 18 years
- •ECOG performance status 0 to 2
- •Life expectancy of at least 12 weeks
- •Disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1)
- •Any prior treatment (chemotherapy, radiation or surgery) must have been completed at least 2 weeks prior to initiation of study medication.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening:
- •- Hemoglobin = 8.0 g/dL
- •- Absolute neutrophil count (ANC) = 1,000 /mm3
- •- Platelet count = 50 000/µL
- •- Total bilirubin = 2 x upper limit of normal (ULN)
- •- Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) = 2,5 x ULN or = 5 x ULN in case of liver involvement
- •- PT-INR/PTT = 1.5 x ULN
- •- Serum creatinine = 2 times ULN
- •-Calculated creatinine clearance (CRCL) = 40 ml/min
- •(Cockcroft-Gault formula)
- •Written informed consent
- •Negative serum pregnancy test within 3 days prior to start of dosing premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for = 1 year.
- •Fertile men and women must have an effective method of contraception during treatment and for at least 3 months after completion of treatment as directed by their physician. Effective methods of contraception result in a low failure rate (i.e. less 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence where lifestyle of the patient ensures compliance (Periodic abstinence and withdrawal are not acceptable methods of contraception).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Previous treatment with specific ALK or ROS1 inhibitors
- •Current treatment within another therapeutic clinical trial
- •Other history of ongoing malignancy that would potentially interfere with the interpretation of efficacy (early stage or chronic disease is allowed if not requiring active therapy or intervention and being under control)
- •Pregnancy or breastfeeding
- •Use of drugs or foods that are known potent CYP3A4 inhibitors, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole and grapefruit or grapefruit juice
- •Use of drugs that are known potent CYP3A4 inducers, including but not limited to carbamazepine, Phenobarbital, phenytoin, rifabutin, rifampin, and St. John’s wort
- •Use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but not limited to dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and terfenadine.
- •Active CNS metastases, patients with brain metastasis are eligible if asymptomatic for = 14 days before starting study medication and off corticosteroids
- •History of or known carinomatous meningitis or leptomeningeal disease
- •Known diagnosis of HIV, active hepatitis B and/or C (testing is not mandatory)
- •Any person being in an institution on assignment of the respective authority against his/her own will
- •Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
- •Ongoing cardiac dysrhythmias of CTCAE grade =2, uncontrolled atrial fibrillation of any grade or QTcF interval > 470ms
- •History of extensive disseminated/bilateral or known presence of interstitial fibrosis or interstitial lung disease of any grade, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior, radiation pneumonitis.
- •Any of the following within 3 months prior to first crizotinib administration:
- •Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
研究者
相似试验
进行中（未招募）
1 期
Treatment of advanced adenocarcinoma of the lungAdult patients with either firstly diagnosed or relapsed advanced adenocarcinoma of the lung harbouring ROS1 translocationMedDRA version: 17.1Level: LLTClassification code 10025032Term: Lung adenocarcinoma NOSSystem Organ Class: 100000004864EUCTR2013-002737-38-ATniversity of Cologne30
进行中（未招募）
1 期
Treatment of advanced lung cancerEUCTR2018-000399-13-DEniversity of Cologne50
进行中（未招募）
1 期
Trastuzumab and AUY922 in HER2-aberrant NSCLCAdvanced non-smallcell lung cancer with HER2 - overexpression or - amplification or - mutationMedDRA version: 17.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005655-13-DEniversity of Cologne29
进行中（未招募）
1 期
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibitiolocally advanced esophageal adenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10001173Term: Adenocarcinoma of esophagusSystem Organ Class: 100000004864EUCTR2018-003048-22-DEniversität zu Köln56
尚未招募
2 期
A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or -amplification or - mutation.HER2-overexpression or -amplification or -mutationC34Malignant neoplasm of bronchus and lungDRKS00003301niversität Köln29